Evidence, support and education needed to drive precision oncology forward, says Accenture’s Bogdan

Improving the uptake of precision medicine in community oncology practices will require a multi-step process to give clinicians the right data and the right support, along with a rethink of how education occurs, according to a global technology leader. medical.

Boris Bogdan, MD, MBA, Managing Director and Global Leader, Medical Practice and Center of Excellence for Precision Oncology, Accenture, discussed a survey of oncologists’ views, along with recommendations on how to strengthen precision medicine, during an interview with Evidence-based oncology™.

Findings and recommendations were included in Accenture’s 2021 report, “The Future is Now: Driving Precision Oncology Adoption.”one The report adds to the chorus calling for more data sharing and better standardization, so that academic centers and community practices can continually improve the data sets used around the world. Accenture’s findings align with discussion with global Real World Evidence (RWE) experts during a symposium at the 63rd Annual Meeting & Exposition of the American Society of Hematology in December 2021.two

Precision oncology is seen as the future of cancer care: the Accenture report cites a 2019 study estimating that up to 50% of patients could benefit from this approach.3 And yet, Accenture’s survey of 130 oncologists in the United States and Europe found that 29% reported that the practice of matching a treatment to a particular patient was not widely adopted in their daily work.one

Spread the love

What do you think?